Scholtz & Company Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$3.42M |
| 2 |
Adobe
ADBE
|
+$3.13M |
| 3 |
Fortinet
FTNT
|
+$2.45M |
| 4 |
GTLS
Chart Industries
GTLS
|
+$2.23M |
| 5 |
Zoetis
ZTS
|
+$2.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Northrop Grumman
NOC
|
+$6.03M |
| 2 |
W.R. Berkley
WRB
|
+$1.99M |
| 3 |
Morgan Stanley
MS
|
+$1.91M |
| 4 |
Microsoft
MSFT
|
+$1.05M |
| 5 |
Marvell Technology
MRVL
|
+$637K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.7% |
| 2 | Consumer Discretionary | 21.83% |
| 3 | Healthcare | 16.15% |
| 4 | Financials | 14.34% |
| 5 | Industrials | 13.33% |
Similar funds
Scholtz & Company's Q2 2023 Portfolio in Review
As of Q2 2023, Scholtz & Company held 42 positions worth $160M, up 14% from $140M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Scholtz & Company deployed $5.39M of net new capital in Q2 2023, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Shockwave Medical, Inc. Common Stock: 12,304 shares worth $3.51M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was W.R. Berkley, an estimated $1.99M trimmed.
- Scholtz & Company's largest Q2 2023 buy was Shockwave Medical, Inc. Common Stock: 12,304 shares worth $3.51M.
- Scholtz & Company added most to Zoetis in Q2 2023, an estimated $2.01M increase.
- Scholtz & Company's biggest Q2 2023 reduction was W.R. Berkley, cutting an estimated $1.99M.
- Scholtz & Company fully exited Northrop Grumman in Q2 2023, selling an estimated $6.03M.
- Scholtz & Company's ten largest holdings make up 58% of its $160M portfolio in Q2 2023.
- Scholtz & Company opened 8 new positions and closed 3 in Q2 2023.
- Scholtz & Company's portfolio value rose 14% quarter-over-quarter to $160M.
Based on Scholtz & Company's 13F filing for Q2 2023, filed 14 Aug 2023.